SCHEMBL4370286

SCHEMBL4370286

COC(=O)[C@@]1(C)[C@@H](O[Si](C)(C)C(C)(C)C)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.32
EPHX1 P07099 1/20 0.32
USP2 O75604 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HSD11B1 P28845 1/20 0.32
ALDH1A1 P00352 1/20 0.31
EPHX2 P34913 1/20 0.31
HPGD P15428 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
HSD17B10 Q99714 1/20 0.30
PTPN2 P17706 1/20 0.30
PTPN1 P18031 1/20 0.30
PTPN6 P29350 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4371143 1.00 RECQL (0.32) RECQLEPHX1USP2SMN1; SMN2HSD11B1
SCHEMBL2964589 1.00 RECQL (0.32) RECQLEPHX1USP2SMN1; SMN2HSD11B1
SCHEMBL2956240 1.00 RECQL (0.32) RECQLEPHX1USP2SMN1; SMN2HSD11B1
SCHEMBL143218 0.88 SMN1; SMN2 (0.33) RECQLEPHX1USP2SMN1; SMN2HPGD
SCHEMBL15512775 0.88 SMN1; SMN2 (0.33) RECQLEPHX1USP2SMN1; SMN2HPGD
SCHEMBL28044757 0.80 EPHX1 (0.37) RECQLEPHX1USP2SMN1; SMN2HSD11B1
SCHEMBL4370444 0.79 RECQL (0.33) RECQLEPHX1USP2SMN1; SMN2ALDH1A1
SCHEMBL4371444 0.79 RECQL (0.33) RECQLEPHX1USP2SMN1; SMN2ALDH1A1
SCHEMBL2958649 0.79 RECQL (0.33) RECQLEPHX1USP2SMN1; SMN2ALDH1A1
SCHEMBL6026102 0.79 RECQL (0.33) RECQLEPHX1USP2SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7625923-B2 Bicyclic modulators of androgen receptor function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-01 US disclosed
US-7625923-B2 Bicyclic modulators of androgen receptor function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-01 US disclosed
EP-1722793-A1 BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION Brystol-Myers Squibb Company (US) 2006-11-22 EP disclosed
WO-2005087232-A1 BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2005-09-22 WO disclosed
US-20050197359-A1 Bicyclic modulators of androgen receptor function BRISTOL-MYERS SQUIBB COMPANY 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197359-A1 Bicyclic modulators of androgen receptor function AR, ESRRA, NR5A1 RECQL 2563/4885EPHX1 3832/4885USP2 3609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.